{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:08:46Z","timestamp":1792804126024,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260573"],"award-info":[{"award-number":["82260573"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX10203207"],"award-info":[{"award-number":["2017ZX10203207"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Key Research and Development Project of Guangxi","award":["AB20297009, AA18221001, AB18050020"],"award-info":[{"award-number":["AB20297009, AA18221001, AB18050020"]}]},{"name":"The Key Laboratory of Early Prevention and Treatment for Regional High-Frequency Tumor, Ministry of Education\/Guangxi, Independent Research Project","award":["GKE2017-ZZ02, GKE2018-KF02, GKE2019-ZZ07"],"award-info":[{"award-number":["GKE2017-ZZ02, GKE2018-KF02, GKE2019-ZZ07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12590-6","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:55:13Z","timestamp":1769522113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of sustained virological response on prognosis after hepatectomy for hepatitis C-related hepatocellular carcinoma: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Pei-shu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-de","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"12590_CR1","doi-asserted-by":"publisher","first-page":"caac70018","DOI":"10.3322\/caac.70018","volume":"20","author":"D Moris","year":"2025","unstructured":"Moris D, Martinino A, Schiltz S, et al. Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians. CA Cancer J Clin Published Online May. 2025;20:caac70018. https:\/\/doi.org\/10.3322\/caac.70018.","journal-title":"CA Cancer J Clin Published Online May"},{"key":"12590_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijsu.2020.03.052","volume":"79","author":"Y Liang","year":"2020","unstructured":"Liang Y, Lin C, Zhang B, et al. Perioperative outcomes comparing laparoscopic with open repeat liver resection for post-hepatectomy recurrent liver cancer: A systematic review and meta-analysis. Int J Surg. 2020;79:17\u201328. https:\/\/doi.org\/10.1016\/j.ijsu.2020.03.052.","journal-title":"Int J Surg"},{"key":"12590_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijsu.2020.06.034","volume":"81","author":"N Lin","year":"2020","unstructured":"Lin N, Li J, Ke Q, Wang L, Liu J. Does intermittent pringle maneuver loss its clinical value in reducing bleeding during hepatectomy? A systematic review and meta-analysis. Int J Surg. 2020;81:158\u201364. https:\/\/doi.org\/10.1016\/j.ijsu.2020.06.034.","journal-title":"Int J Surg"},{"issue":"30","key":"12590_CR4","doi-asserted-by":"publisher","first-page":"48948","DOI":"10.18632\/oncotarget.16896","volume":"8","author":"P Chen","year":"2017","unstructured":"Chen P, Wang F, Feng J, et al. Co-expression network analysis identified six hub genes in association with metastasis risk and prognosis in hepatocellular carcinoma. Oncotarget. 2017;8(30):48948\u201358. https:\/\/doi.org\/10.18632\/oncotarget.16896.","journal-title":"Oncotarget"},{"key":"12590_CR5","doi-asserted-by":"publisher","unstructured":"Cobb BR, Valsamakis A. Chronic Hepatitis B, C, and D. Hayden RT, Wolk DM, Carroll KC, Tang YW, eds. Microbiol Spectr. 2016;4(4):4.4.25. https:\/\/doi.org\/10.1128\/microbiolspec.DMIH2-0025-2015.","DOI":"10.1128\/microbiolspec.DMIH2-0025-2015"},{"issue":"6","key":"12590_CR6","doi-asserted-by":"publisher","first-page":"106298","DOI":"10.1016\/j.jinf.2024.106298","volume":"89","author":"B Wen","year":"2024","unstructured":"Wen B, Te L, Bai C, et al. Relative contribution of hepatitis B and C viruses in primary liver cancer in china: a systematic review and meta-analysis. J Infect. 2024;89(6):106298. https:\/\/doi.org\/10.1016\/j.jinf.2024.106298.","journal-title":"J Infect"},{"issue":"11","key":"12590_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/apt.17438","volume":"57","author":"WY Kao","year":"2023","unstructured":"Kao WY, Tan ECH, Lee HL, et al. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther. 2023;57(11):1299\u2013312. https:\/\/doi.org\/10.1111\/apt.17438.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"12590_CR8","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1097\/JS9.0000000000000554","volume":"109","author":"H Linye","year":"2023","unstructured":"Linye H, Zijing X, Xiaoyun Z, Zhihui L, Tianfu W, Chuan L. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial. Int J Surg Lond Engl. 2023;109(10):3032\u201341. https:\/\/doi.org\/10.1097\/JS9.0000000000000554.","journal-title":"Int J Surg Lond Engl"},{"issue":"18","key":"12590_CR9","doi-asserted-by":"publisher","first-page":"14404","DOI":"10.3390\/ijms241814404","volume":"24","author":"JV Lazarus","year":"2023","unstructured":"Lazarus JV, Picchio CA, Colombo M. Hepatocellular carcinoma prevention in the era of hepatitis C elimination. Int J Mol Sci. 2023;24(18):14404. https:\/\/doi.org\/10.3390\/ijms241814404.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"12590_CR10","doi-asserted-by":"publisher","first-page":"101145","DOI":"10.1016\/j.jhepr.2024.101145","volume":"6","author":"A Herranz Mochales","year":"2024","unstructured":"Herranz Mochales A, Picchio CA, Nicol\u00e0s A, et al. Implementing a new HCV model of care for people who use drugs. JHEP Rep. 2024;6(10):101145. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101145.","journal-title":"JHEP Rep"},{"issue":"7","key":"12590_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jvh.13681","volume":"29","author":"A Kuwano","year":"2022","unstructured":"Kuwano A, Yada M, Nagasawa S, et al. Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib. J Viral Hepat. 2022;29(7):543\u201350. https:\/\/doi.org\/10.1111\/jvh.13681.","journal-title":"J Viral Hepat"},{"issue":"10","key":"12590_CR12","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.3390\/life13101964","volume":"13","author":"WC Tsai","year":"2023","unstructured":"Tsai WC, Chiang HC, Chiu YC, Chien SC, Cheng PN, Chiu HC. Chronic hepatitis C virus infection: an ongoing challenge in screening and treatment. Life. 2023;13(10):1964. https:\/\/doi.org\/10.3390\/life13101964.","journal-title":"Life"},{"issue":"3","key":"12590_CR13","doi-asserted-by":"publisher","first-page":"101626","DOI":"10.1016\/j.clinre.2021.101626","volume":"45","author":"S Roger","year":"2021","unstructured":"Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol. 2021;45(3):101626. https:\/\/doi.org\/10.1016\/j.clinre.2021.101626.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"12590_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2018.09.029","volume":"70","author":"M Nishibatake Kinoshita","year":"2019","unstructured":"Nishibatake Kinoshita M, Minami T, Tateishi R, et al. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy. J Hepatol. 2019;70(1):78\u201386. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.029.","journal-title":"J Hepatol"},{"issue":"4","key":"12590_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","volume":"65","author":"Lack of evidence of","year":"2016","unstructured":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.045.","journal-title":"J Hepatol"},{"issue":"4","key":"12590_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2016.06.015.","journal-title":"J Hepatol"},{"issue":"5","key":"12590_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jhep.2021.01.046","volume":"74","author":"M Reig","year":"2021","unstructured":"Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol. 2021;74(5):1225\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.046.","journal-title":"J Hepatol"},{"issue":"3","key":"12590_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2020.03.030","volume":"73","author":"A Sangiovanni","year":"2020","unstructured":"Sangiovanni A, Alimenti E, Gattai R, et al. Undefined\/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. J Hepatol. 2020;73(3):593\u2013602. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.030.","journal-title":"J Hepatol"},{"key":"12590_CR19","doi-asserted-by":"publisher","unstructured":"Zhou J, Sun H, Wang Z, et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition). Liver cancer. Published Online July. 2025;10. https:\/\/doi.org\/10.1159\/000546574.","DOI":"10.1159\/000546574"},{"key":"12590_CR20","doi-asserted-by":"publisher","unstructured":"Ahmad J, Hepatitis C. BMJ. Published online July 6, 2017:j2861. https:\/\/doi.org\/10.1136\/bmj.j2861","DOI":"10.1136\/bmj.j2861"},{"issue":"3","key":"12590_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/COH.0000000000000370","volume":"12","author":"PJ Easterbrook","year":"2017","unstructured":"Easterbrook PJ, Roberts T, Sands A, Peeling R. Diagnosis of viral hepatitis. Curr Opin HIV AIDS. 2017;12(3):302\u201314. https:\/\/doi.org\/10.1097\/COH.0000000000000370.","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"12590_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3350\/cmh.2021.0193","volume":"28","author":"HW Lee","year":"2022","unstructured":"Lee HW, Lee H, Kim BK, Chang Y, Jang JY, Kim DY. Cost-effectiveness of chronic hepatitis C screening and treatment. Clin Mol Hepatol. 2022;28(2):164\u201373. https:\/\/doi.org\/10.3350\/cmh.2021.0193.","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"12590_CR23","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"JM Pawlotsky","year":"2020","unstructured":"Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. J Hepatol. 2020;73(5):1170\u2013218. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.018.","journal-title":"J Hepatol"},{"issue":"2","key":"12590_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/apt.13034","volume":"41","author":"CCN Chong","year":"2015","unstructured":"Chong CCN, Wong GLH, Wong VWS, et al. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther. 2015;41(2):199\u2013208. https:\/\/doi.org\/10.1111\/apt.13034.","journal-title":"Aliment Pharmacol Ther"},{"issue":"20","key":"12590_CR25","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.3748\/wjg.v20.i20.6006","volume":"20","author":"CCN Chong","year":"2014","unstructured":"Chong CCN, Wong GLH, Lai PBS. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. World J Gastroenterol WJG. 2014;20(20):6006\u201312. https:\/\/doi.org\/10.3748\/wjg.v20.i20.6006.","journal-title":"World J Gastroenterol WJG"},{"issue":"5","key":"12590_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/jcm14051505","volume":"14","author":"S Bucurica","year":"2025","unstructured":"Bucurica S, Nancoff AS, Marin RI, Preda CM. Hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis treated with DAA: A focused review. J Clin Med. 2025;14(5):1505. https:\/\/doi.org\/10.3390\/jcm14051505.","journal-title":"J Clin Med"},{"issue":"5","key":"12590_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/2050640619841254","volume":"7","author":"CM Preda","year":"2019","unstructured":"Preda CM, Baicus C, Sandra I, et al. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir\/paritaprevir\/ritonavir\u2009+\u2009dasabuvir\u2009+\u2009ribavirin therapy. United Eur Gastroenterol J. 2019;7(5):699\u2013708. https:\/\/doi.org\/10.1177\/2050640619841254.","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"12590_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2018","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68(1):25\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.030.","journal-title":"J Hepatol"},{"issue":"6","key":"12590_CR29","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204\u201312. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.025.","journal-title":"J Hepatol"},{"issue":"4","key":"12590_CR30","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jhep.2017.07.007","volume":"67","author":"P Kolly","year":"2017","unstructured":"Kolly P, Waidmann O, Vermehren J, et al. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. J Hepatol. 2017;67(4):876\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.007.","journal-title":"J Hepatol"},{"issue":"22","key":"12590_CR31","doi-asserted-by":"publisher","first-page":"16048","DOI":"10.3390\/ijms242216048","volume":"24","author":"I Milosevic","year":"2023","unstructured":"Milosevic I, Todorovic N, Filipovic A, et al. HCV and HCC Tango-Deciphering the intricate dance of disease: A review Article. Int J Mol Sci. 2023;24(22):16048. https:\/\/doi.org\/10.3390\/ijms242216048.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12590_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primer. 2021;7(1):6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"12590_CR33","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1053\/jhep.2003.50399","volume":"38","author":"T Tsutsumi","year":"2003","unstructured":"Tsutsumi T, Suzuki T, Moriya K, et al. Hepatitis C virus core protein activates ERK and p38 MAPK in Cooperation with ethanol in Transgenic mice. Hepatol Baltim Md. 2003;38(4):820\u20138. https:\/\/doi.org\/10.1053\/jhep.2003.50399.","journal-title":"Hepatol Baltim Md"},{"key":"12590_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/JHC.S221187","volume":"7","author":"S Dash","year":"2020","unstructured":"Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of Direct-Acting antiviral treatment. J Hepatocell Carcinoma. 2020;7:45\u201376. https:\/\/doi.org\/10.2147\/JHC.S221187.","journal-title":"J Hepatocell Carcinoma"},{"issue":"6","key":"12590_CR35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and cancer. Cell. 2010;140(6):883\u201399. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025.","journal-title":"Cell"},{"issue":"1","key":"12590_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jvh.13204","volume":"27","author":"TL Laursen","year":"2020","unstructured":"Laursen TL, Siggaard CB, Kazankov K, et al. Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepat. 2020;27(1):28\u201335. https:\/\/doi.org\/10.1111\/jvh.13204.","journal-title":"J Viral Hepat"},{"issue":"2","key":"12590_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.17998\/jlc.2022.05.24","volume":"22","author":"YH Ahn","year":"2022","unstructured":"Ahn YH, Lee H, Han JE, et al. Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment. J Liver Cancer. 2022;22(2):125\u201335. https:\/\/doi.org\/10.17998\/jlc.2022.05.24.","journal-title":"J Liver Cancer"},{"issue":"10","key":"12590_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.cmi.2016.07.019","volume":"22","author":"T Vescovo","year":"2016","unstructured":"Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus\u2013induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22(10):853\u201361. https:\/\/doi.org\/10.1016\/j.cmi.2016.07.019.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"12590_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2468-1253(22)00009-7","volume":"7","author":"G Dusheiko","year":"2022","unstructured":"Dusheiko G, Carey I. Global elimination of hepatitis C: a warning from the data. Lancet Gastroenterol Hepatol. 2022;7(5):380\u20131. https:\/\/doi.org\/10.1016\/S2468-1253(22)00009-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"13","key":"12590_CR40","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1245\/s10434-019-07911-w","volume":"26","author":"Y Okamura","year":"2019","unstructured":"Okamura Y, Sugiura T, Ito T, et al. The achievement of a sustained virological response either before or after hepatectomy improves the prognosis of patients with primary hepatitis C virus-related hepatocellular carcinoma. Ann Surg Oncol. 2019;26(13):4566\u201375. https:\/\/doi.org\/10.1245\/s10434-019-07911-w.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"12590_CR41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-024-16453-9","volume":"32","author":"H Abe","year":"2025","unstructured":"Abe H, Okamura Y, Yoshida N, et al. Impact of sustained virological response on long-term outcomes after curative resection in patients with hepatitis C virus-related hepatocellular carcinoma in the era of direct-acting antiviral therapy. Ann Surg Oncol. 2025;32(2):1093\u2013104. https:\/\/doi.org\/10.1245\/s10434-024-16453-9.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"12590_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/ijms23010500","volume":"23","author":"FP Russo","year":"2022","unstructured":"Russo FP, Zanetto A, Pinto E, et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int J Mol Sci. 2022;23(1):500. https:\/\/doi.org\/10.3390\/ijms23010500.","journal-title":"Int J Mol Sci"},{"key":"12590_CR43","doi-asserted-by":"publisher","first-page":"23760","DOI":"10.1038\/s41598-024-75280-w","volume":"14","author":"X Zhu","year":"2024","unstructured":"Zhu X, Jia L, Yue M, et al. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C. Sci Rep. 2024;14:23760. https:\/\/doi.org\/10.1038\/s41598-024-75280-w.","journal-title":"Sci Rep"},{"issue":"2","key":"12590_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","volume":"71","author":"G Cabibbo","year":"2019","unstructured":"Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71(2):265\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.027.","journal-title":"J Hepatol"},{"issue":"1","key":"12590_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/liv.12576","volume":"35","author":"E Akhtar","year":"2015","unstructured":"Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35(1):30\u20136. https:\/\/doi.org\/10.1111\/liv.12576.","journal-title":"Liver Int"},{"issue":"11","key":"12590_CR46","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/hepr.13709","volume":"51","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Shinkawa H, Tamori A, et al. Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma. Hepatol Res Off J Jpn Soc Hepatol. 2021;51(11):1102\u201314. https:\/\/doi.org\/10.1111\/hepr.13709.","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"issue":"3","key":"12590_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"issue":"5","key":"12590_CR48","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jhep.2022.02.026","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Bruix J. Reply to: correspondence on the <\u2009BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update>. J Hepatol. 2022;76(5):1240\u20131. https:\/\/doi.org\/10.1016\/j.jhep.2022.02.026.","journal-title":"J Hepatol"},{"issue":"6","key":"12590_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4097\/kja.19087","volume":"72","author":"JH Kim","year":"2019","unstructured":"Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72(6):558\u201369. https:\/\/doi.org\/10.4097\/kja.19087.","journal-title":"Korean J Anesthesiol"},{"issue":"12","key":"12590_CR50","doi-asserted-by":"publisher","first-page":"e0167934","DOI":"10.1371\/journal.pone.0167934","volume":"11","author":"R Villani","year":"2016","unstructured":"Villani R, Facciorusso A, Bellanti F, et al. DAAs rapidly reduce inflammation but increase serum VEGF level: A rationale for tumor risk during Anti-HCV treatment. PLoS ONE. 2016;11(12):e0167934. https:\/\/doi.org\/10.1371\/journal.pone.0167934.","journal-title":"PLoS ONE"},{"issue":"1","key":"12590_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000490360","volume":"8","author":"S Owusu Sekyere","year":"2019","unstructured":"Owusu Sekyere S, Schlevogt B, Mettke F, et al. HCC immune surveillance and antiviral therapy of hepatitis C virus infection. Liver Cancer. 2019;8(1):41\u201365. https:\/\/doi.org\/10.1159\/000490360.","journal-title":"Liver Cancer"},{"issue":"6","key":"12590_CR52","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N, et al. Direct-Acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology. 2019;156(6):1683\u20131692.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.027.","journal-title":"Gastroenterology"},{"issue":"8","key":"12590_CR53","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral Direct-Acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019;156(8):2149\u201357. https:\/\/doi.org\/10.1053\/j.gastro.2019.02.046.","journal-title":"Gastroenterology"},{"issue":"5","key":"12590_CR54","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","volume":"155","author":"P Nahon","year":"2018","unstructured":"Nahon P, Layese R, Bourcier V, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155(5):1436\u20131450.e6. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.015.","journal-title":"Gastroenterology"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12590-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:07:59Z","timestamp":1771420079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12590-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12590"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12590-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The research protocol was reviewed and approved by the Medical Ethics Committee of Guangxi Medical University Cancer Hospital, confirming its compliance with medical ethics requirements (Approval No. KY2025798). Written informed consent was obtained from all enrolled participants. The requirement for informed consent was waived by our Institutional Review Board because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"397"}}